Dr Anand Deshpande P D Hinduja National Hospital & MRC Mumbai.

Slides:



Advertisements
Similar presentations
Coagulopathy and blood component transfusion in trauma
Advertisements

High Throughput Donor Plasma NAT Screening Assay Applied to Acute HIV Detection in a Public Health Setting December 5, 2007 Josh Goldsmith, Ph.D. National.
GENERAL AWARENESS ON HIV/AIDS Presented by: WeHELP In Association with its MEDICAL TEAM.
Infection control Antiseptics and disinfectants Antiseptics and disinfectants.
Experience of the Irish Blood Transfusion Service William G. Murphy MD
Update on the AABB Standards and platelet bacterial contamination TAC: MVRBC 2011.
Leucocyte depleted blood products. BCSH;Transfusion Medicine, 1998,8,59-71 Dr. Tariq Roshan 23 rd March 2003.
Hello. Blood Transfusion What is a Blood Transfusion? Blood transfusion is a medical procedure that needs to be ordered by a physician. It is the introduction.
1 1.
BLOOD BANKING 1- BLOOD PRODUCTS 2- AUTOLOGOUS TRANSFUSION M. H. Shaheen Maadi Armed Forces Hospital.
A summary review provided by the American Red Cross Blood Services Regions serving the North Atlantic Area July, 2003 Bacterial Contamination in Blood.
Single-Donor Platelets: Arguments for Preferential Use Paul M. Ness, MD Transfusion Medicine Division Johns Hopkins Medical Institutions.
The Progression of Liver Fibrosis is Associated with the Severity of the HIV Disease in HIV-HCV Co-infected Female Patients Mohammad K. Mohammad 1, Babu.
Is Nucleic Acid Testing for Organ Donors the ‘Right’ Choice? Reference: Humara A, Morrisb M, Blumbergc R, et al. Nucleic acid testing (NAT) of organ donors:
Transfusion Transmission of HIV 1. Past & Current Risk Estimates of Transfusion-Transmitted HIV Infection 2. Layers of Safety in Protection of the Blood.
F. Kourgia, M. Vini, E. Zervou
Dengue Virus and Its Risk to the U.S. Blood Supply
THE RATIONAL USE OF BLOOD AND BLOOD PRODUCTS
HIV Testing CDC power point edited by M. Myers
Terry Kotrla, MS, MT(ASCP)BB MLAB 2431 Immunohematology Unit 1 Part 2 Blood Collection.
Transfusion of Blood Product History: 1920:Sodium citrate anticoagulant(10 days storage) 1958: Plastic bag of transfusion 1656: Initial theory and.
Immunohematology (Blood Bank) CLS 245. What is Immunohematology? It is the study of Antigen-Antibody reaction as they relate to blood disorder.
HIV Testing Quality Assurance and Quality Control
Risks and Indications for RBCs Transfusions David Stroncek, MD Chief, Laboratory Services Section Department of Transfusion Medicine, Clinical Center,
The Journey of Blood. Blood - the life source Slide 1: Blood is a scarce and vital resource which saves lives and improves the health of millions. Its.
21 August 2015 Samreen Ijaz Virus Reference Department Health Protection Agency Indigenous HEV infection in the UK: a hazard for blood donation?
Chapter 24; Lesson 3.  Human Immunodeficiency Virus (HIV) – a virus that attacks the immune system.  Once HIV enters the body, it finds and destroys.
+ Dr. Megan Rowley Consultant in Transfusion Medicine Blood Transfusion.
Types of vaccines 1 - First generation vaccines are whole-organism vaccines - either live and weakened, or killed forms. [1] Live, attenuated vaccines,
FDA’s Current Considerations of Parvovirus B19 Nucleic Acid Testing (NAT) Mei-ying W. Yu, PhD Division of Hematology CBER/FDA Extraordinary SoGAT Meeting.
New Treatment Modalities; Recombinant Factor VIII Products – “Factor VIII after 2008” (More Choices) Gita V. Massey, MD June 20, 2009.
IN THE NAME OF GOD Blood Safety S. AMINI KAFI ABAD CLINICAL AND ANATOMICAL PATHOLOGIST IRANIAN BLOOD TRANSFUSION ORGANIZATION(IBTO) RESEARCH CENTER June.
1 Verax Biomedical Platelet PGD ® Test. 2 Verax Biomedical Platelet PGD ® Test Results in approximately 30 minutes Designed for use with LR or non-LR:
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 83 Basic Principles of Antimicrobial Therapy.
Why Special Blood Products?
21th VHPB meeting on “Prevention of viral hepatitis in Italy: lessons learnt and the way forward” Catania, 7-8 november 2002 RESIDUAL RISK OF TRANSFUSION-
MEDICAL TESTING Doctor requires information Patient sample collection
The Journey of Blood. Blood- the life source Slide 1: Blood is a scarce and vital national resource which cannot be synthesized. About 80 million unit.
© 2007 McGraw-Hill Higher Education. All rights reserved. Wound Care and Bloodborne Pathogens Amber Giacomazzi, MS, ATC.
اعداد / يوسف عبدالله الشمراني اشراف / د 0 هشام ابو عوده.
Progress in West Nile virus Testing and Donor Screening Hira Nakhasi, Ph.D. Director, DETTD/OBRR CBER, FDA.
Leukocyte-Reduced Blood Components Lore Fields MT(ASCP)SBB Consumer Safety Officer, DBA, OBRR, CBER September 16, 2009.
 The overall prevalence of UTI is approximately 2.1 percent in febrile infants but varies widely by race and sex.  Caucasian children have a two- to.
Antigens Antibody Reaction. Complement Fixation Test.
1 Counseling and HIV Testing HAIVN Harvard Medical School AIDS Initiatives in Vietnam.
Module 1: The Journey of Blood: Donation to Distribution Transfusion Training Workshop KKM 2012.
Definition of infection control in dental clinic By: dr.suzan Hassan Lecture (1)
Preparation of blood components
professor in microbiology
HIV is the virus that causes AIDS, a disease that weakens the body’s immune system and may have fatal consequences.
Minimizing the Risks of TSE Agents in Human Tissues Melissa A. Greenwald, M.D. Division of Human Tissues Office of Cellular, Tissue and Gene Therapies;
Jaro Vostal, MD, PhD Division of Hematology, OBRR, CBER, FDA
FDA Perspective on the PASSPORT Study FDA Perspective on the PASSPORT Study Salim A. Haddad, M.D. Laboratory of Cellular Hematology Division of Hematology.
Gülden Çelik. Learning Objectives At the end of this lecture, the student should be able to: Define bacteremia, fungemia, and sepsis List the main types.
February 24, 2016 | 1 Paul Strengers MD, FFPM Sanquin Blood Supply Amsterdam The Netherlands Risk assessment schemes: Impact of.
Michael R. Jacobs, MD, PhD Roslyn Yomtovian, MD
Platelet Transfusions Indications, dose and administration
UNIT REVIEW Bacteria, Gram Staining, Food Safety, & Immunology.
Allogeneic donor selection and blood collection by Mohammed Abu-basha 1.
Blood Transfusion Products. Learning Objectives  To identify the products that can be derived from whole blood donations  To describe the conditions.
COMPARISON OF LABORATORY DIAGNOSTIC PROCEDURES FOR DETECTION OF MYCOPLASMA PNEUMONIAE IN COMMUNITY OUTBREAKS KATHLEEN A. THURMAN, NICHOLAS D. WALTER, STEPHANIE.
MICROBIOLOGY IRS. Gastroenteritis 1) Major cause of infantile death 2) Feacal-oral transmission 3) Gastroenteritis cause dehydration 4) 50 % of all causes.
Compatibility Testing
BLOOD TRANSFUSION An overview
Implant Associated Infections & Sterilization Methods
Pathogen Reduced Platelets: The Next Big Thing in Transfusion Safety
Intraoperative Cell Salvage
Cerebrospinal fluid Culture
Cerebrospinal fluid Culture
Presentation transcript:

Dr Anand Deshpande P D Hinduja National Hospital & MRC Mumbai

 While the blood bank community has successfully implemented the high standards of blood screening for viral markers including NAT screening, transmission of donor bacteria has clearly emerged as the greatest infectious risk to transfusion safety  Bacterial contamination of blood products is a persistent but often overlooked problem in Transfusion Medicine

The dramatic decrease in risk of transfusion-transmitted viral disease was accomplished by conversion from Paid to volunteer whole blood donors in the 1970s. Increased direct questioning of donors regarding risks for the Viruses and increased testing of collected donor blood for antibodies, antigens and nucleic acid of these viruses starting in the 1970s. Risk of hepatitis B may decrease further with universal childhood vaccination. Not shown in the graph are the rare risks of other transmissible diseases. The dashed line indicates the unknown risks, if any, of new viruses and other potentially emerging pathogens, such as prions that cause new variant Creutzfeldt-Jakob Disease. (J of Am Med Ass, Feb 2001, Volume 285, No 5; 579

“SHOT” DATA

CAP CHECKLIST – TRM.44955PHASE II Does the laboratory have a validated system to detect the presence of bacteria in platelet concentrates ? For random donor platelets, any of the following testing methods satisfy this checklist question: detection of decreased pH or glucose by analytic instrument or dipstick; gram stain; acridine orange stain. Though of low sensitivity, these methods may detect units that are heavily contaminated by bacteria. Culture or FDA- approved commercial detection systems have greater sensitivity. The swirling technique is not recommended because of its very low sensitivity.

CAP CHECKLIST – TRM – Revised (Nov 2011)PHASE II Bacterial Contamination in Platelets The enhanced sensitivity requirement reflects the availability of multiple FDA-cleared quality control strategies; insensitive methods including pH, glucose and microscopy are no longer acceptable. Equivalent system is defined as a system that has been validated to demonstrate comparable or improved sensitivity in CFU/mL. If this testing is performed by the supplier of platelet components, the laboratory can satisfy this checklist requirement by having an agreement with the supplier to be notified of supply units suspected of containing bacteria.

Origin of bacteria  From donor –  Unsuspected bacterimia  Venipuncture site  Rarely during processing and storage  At the time of transfusion

Risk estimates  HIV / HCV / HAV – 1 in a few million  HBV – 1 in 0.3 million  Bacteria (RBCs) – 1 in 30,000  Bacteria (Platelets) – 1 in 3000

Organisms in RBC component  Yersinia entercolotica, Serratia & Pseudomonas  Y. enterocolitis – fever, diarrhea – Endotoxins  Initial lag phase – rapidly proliferative after 20 – 25 days of storage  25 fatalities reported in USA (1995 – 2004)  Risk of death – 0.13 / million  Autologous

Transfusion fatalities by organisms in Red cell transfusions (25)

Summary of Organisms from RBC Transfusions identified in the BACON, SHOT and BACTHEM studies

Organisms in Platelet component  times higher risk than viral infection  Room temperature storage  Organisms are varied – coagulase negative staphylococcus commonest, Bacillus  Contamination risk is 1:3000 approx, whereas Septic reactions occur in 1/4 th to 1/6 th of the contaminated platelets  Fatalities – gram negative organisms  Clinically, Fever-Hypertension-Sepsis-Death  Sometimes difficult to diagnose

Plasma / Cryo  Frozen state  Rarely associated with contamination

Strategies to reduce risk of post transfusion sepsis BBacterial Avoidance GGrowth inhibition DDetection EElimination

I. Bacterial Avoidance A] Donor screening  Careful selection of healthy blood donors  Recent dental procedures  Recent use of antibiotics/Medical & surgical interventions  Problems – e.g. Yersinia sepsis – retrospective analysis – 50 % donors had GI symptoms  Special considerations – Autologous blood units

Bacterial avoidance B] Skin preparations  Not possible to have sterile venipuncture  Sebaceous glands / Hair follicles  Scarring or dimpling  Isopropyl alcohol + Iodine + Isopropyl alcohol  Chlorhexidine

Percentage of Donors with Bacteria growth after skin disinfection

Bacterial avoidance C] Diversion  Significant reduction in blood contamination if first ml of blood is diverted to the pouch  Study from Netherlands – 0.35 % %  Expected to reduce gram positive organisms

Apheresis vs WBD platelets  Significant reduction in sepsis (John Hopkins study)  1:4818  1:  Cultures with apheresis platelets

II. Growth inhibitors … Optimising storage temperature  Red cells (1 0 – 6 0 C) – Yersinia / Serratia  Frozen - ? Practicality  Platelets – (20 0 – 24 0 C)  4 0 C – Temperature induced activation

Growth inhibition …Optimising storage time A. Red Cells  Yersinia sepsis in units > 25 days old  Proposed to reduce shelf life for 25 days  Rejected – 20 % units > 25 days - Recruiting new donor - Units < 25 days also causes sepsis

B. Platelets  Ideal would be 1 – 2 days  Diagnostic disease markers – impossible (NAT/Culture)

III. Bacterial detection  No ideal procedure for detection of bacteria  Limitations  Short shelf life of 5 days  The amount of bacterimia changes with time  Contamination may occur during sampling processes  Innoculation may be very small

 Bacterial genome detection – NAT  Bacterial culture – most reliable method – 24 hrs

IV. Bacterial elimination Leucodepletion by filtration  Prestorage leucocyte filters  Related to leucocyte phagocytosis  Related to direct filter binding mechanism  No evidence that prestorage leucocyte reduction by filtration contributed to bacterial proliferation

V. Pathogen inactivation  Final common pathway  Photodynamic and photochemical methods

UK experience - Poster at Cancun – ISBT  1996 – 2010 – 40 cases – SHOT  33/40 – platelet transfusion  9/33 – fatalities  NHS – BacT / ALERT for culture  0.03% confirmed positive  No report of transmission of bacteria by transfusion of platelets in 2011

Factors affecting outcome of Transfusion of Bacterially contaminated blood components

Under reporting  Septic or fatal reaction – elderly, neonates or patients immunocompromised by illness or chemo  If patients on antimicrobial therapy -  severity  Low levels of bacterial contamination causes mild symptoms like fever and chills – resembling FNHTRs

Conclusion …….  Significant progress in understanding  Source reduction by good skin preparation and diversion pouch  Better and specific method like Bact culture  Towards safer blood and better patient care ……………

Conclusion  There is always another pathogen waiting its turn  A zero-risk blood supply is not achievable  The safest transfusion is still the one not infused……………….